Adverse Events of Lutetium-177-PSMA-617 Revealed
Lutetium-177-PSMA-617 (Pluvicto®) has emerged as a groundbreaking radiolabeled therapeutic agent in the battle against advanced prostate cancer, specifically targeting metastatic ...
Lutetium-177-PSMA-617 (Pluvicto®) has emerged as a groundbreaking radiolabeled therapeutic agent in the battle against advanced prostate cancer, specifically targeting metastatic ...
In a significant advancement for prostate cancer treatment, the Phase III clinical trial NRG-GU005 has shed new light on the ...
In a groundbreaking study published in Annals of Biomedical Engineering, researchers have unveiled a promising novel approach in the treatment ...
For men undergoing radical prostatectomy to treat prostate cancer, the decision to follow surgery with radiation therapy can be a ...
In a landmark advancement in prostate cancer treatment, a pivotal phase III clinical trial has demonstrated that a condensed course ...
Investigators at the renowned UCLA Health Jonsson Comprehensive Cancer Center have made a significant breakthrough in the realm of prostate ...
A recent seminal study conducted by UCLA Health Jonsson Comprehensive Cancer Center researchers has illuminated a significant breakthrough in the ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine